Multiple electrode aggregometry as a method for platelet function assessment according to the European guidelines

Pluta, Jan; Nicińska, Barbara; Trzebicki, Janusz

doi:10.5603/ait.a2018.0024

Cited by 8 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in general, MEA and whole blood aggregometry correlate only moderately well with LTA, and there is debate over MEA's ability to predict clinical outcomes. As such, LTA continues to be considered the criterion standard in platelet aggregation function testing (2,45,50,51).…”

Section: Multiple Electrode Aggregometry and Multiplate Analyzermentioning

confidence: 99%

Platelet Function in Trauma: Is Current Technology in Function Testing Missing the Mark in Injured Patients?

Schriner

George

Cardenas

et al. 2022

Shock

View full text Add to dashboard Cite

Platelets are subcellular anucleate components of blood primarily responsible for initiating and maintaining hemostasis. After injury to a blood vessel, platelets can be activated via several pathways, resulting in changed shape, adherence to the injury site, aggregation to form a plug, degranulation to initiate activation in other nearby platelets, and acceleration of thrombin formation to convert fibrinogen to fibrin before contracting to strengthen the clot. Platelet function assays use agonists to induce and measure one or more of these processes to identify alterations in platelet function that increase the likelihood of bleeding or thrombotic events. In severe trauma, these assays have revealed that platelet dysfunction is strongly associated with poor clinical outcomes. However, to date, the mechanism(s) causing clinically significant platelet dysfunction remain poorly understood. We review the pros, cons, and evidence for use of many of the popular assays in trauma, discuss limitations of their use in this patient population, and present approaches that can be taken to develop improved functional assays capable of elucidating mechanisms of trauma-induced platelet dysfunction. Platelet dysfunction in trauma has been associated with need for transfusions and mortality; however, most of the current platelet function assays were not designed for evaluating trauma patients, and there are limited data regarding their use in this population. New or improved functional assays will help define the mechanisms by which platelet dysfunction occurs, as well as help optimize future treatment.

show abstract

Section: Multiple Electrode Aggregometry and Multiplate Analyzermentioning

confidence: 99%

Platelet Function in Trauma: Is Current Technology in Function Testing Missing the Mark in Injured Patients?

Schriner

George

Cardenas

et al. 2022

Shock

View full text Add to dashboard Cite

show abstract

“…In order to perform MEA, an agonist of a particular pathway of activation is added to whole blood samples with anticoagulantcitrate or hirudin. What is important, MEA can be used in the assessment of platelet functions of patients on various antiplatelet drugs-ASA, P2Y 12 inhibitors, or GPIIb/IIIa receptor blockers (Pluta et al, 2018).…”

Section: Determination Of Platelet Function On Antiplatelet Therapymentioning

confidence: 99%

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by specific gene modifications. Platelets are the major source for circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology. MiRNAs have been shown to modify the expression of platelet proteins influencing platelet reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers of platelet reactivity during antiplatelet therapy as well as novel therapeutic targets in cardiovascular diseases (CVDs). Herein, we review diagnostic and prognostic value of miRNAs levels related to platelet reactivity based on human studies, presenting its interindividual variability as well as the substantial role of genetics. Furthermore, we discuss antiplatelet treatment in the context of miRNAs alterations related to pathways associated with drug response.

show abstract

“…It evaluates the platelet function of several pathways of platelet adhesion and aggregation, and it is dependent on cyclooxygenase (ASPItest, Aspirin®; arachidonic acid), collagen (COLtest), adenosine diphosphate (ADPtest), thrombin (TRAPtest, thrombin receptor activating peptide), and von Willebrand factor (RISTOtest, ristocetin). 17,18 The Multiplate RISTOtest because of its POC availability and specificity for vWF, could be used to diagnose vWF deficiency in patients with bleeding complications during ECMO support. 19,20 However, the gold standards for diagnosing vWF deficiency are special hematological tests such as the quantification of vWF antigen (vWF : Ag), vWF ristocetin cofactor activity assay (vWF : RCo), 21,22 and vWF collagen-binding capacity assay (vWF : CB).…”

Section: Introductionmentioning

confidence: 99%

“…Multiplate analyzers enable the testing of primary hemostasis (platelet clot formation in “low shear stress” conditions that are dependent on platelet adhesion and aggregation). It evaluates the platelet function of several pathways of platelet adhesion and aggregation, and it is dependent on cyclooxygenase (ASPItest, Aspirin®; arachidonic acid), collagen (COLtest), adenosine diphosphate (ADPtest), thrombin (TRAPtest, thrombin receptor activating peptide), and von Willebrand factor (RISTOtest, ristocetin) 17,18 . The Multiplate RISTOtest because of its POC availability and specificity for vWF, could be used to diagnose vWF deficiency in patients with bleeding complications during ECMO support 19,20 .…”

Section: Introductionmentioning

confidence: 99%

Extracorporeal membrane oxygenation seems to induce impairment of primary hemostasis pathology as measured by a Multiplate analyzer: An observational retrospective study

et al. 2021

View full text Add to dashboard Cite

Background: Extracorporeal membrane oxygenation (ECMO) support is often associated with bleeding complications caused by secondary or primary hemostasis pathology. However, there are limited data investigating primary hemostasis using Multiplate aggregometry with specific diagnostics tests for vWF (von Willebrand factor) deficiency. Aims:The aim of this study was to find out whether short-term ECMO produces the pathology of primary hemostasis that is detected by Multiplate aggregometry and to investigate the pathology of vWF.Methods: In this study, blood samples of 20 patients undergoing lung transplantations with short-term perioperative ECMO support were analyzed. The multimeric structure, the levels of von Willebrand factor antigen (vWF), ristocetin cofactor (RCo), collagen-binding protein (CB), and the results of multiple electrode aggregometry RISTO (ristocetin), ADP (adenosine diphosphate), ASPI (Aspirin®; arachidonic acid), and TRAP (thrombin receptor activating peptide) tests were compared to the samples obtained before and after ECMO support. Results:The Multiplate ADP and RISTO tests showed the presence of significant pathology in primary hemostasis after surgery (p < 0.05), suggesting the presence of acquired platelet dysfunction. Although the RISTO tests suggest the presence of acquired vWF deficiency, laboratory tests for vWF antigen and RCo and CB tests showed an increase in this case. The multimeric structure of vWF did not show clinically significant deterioration.Conclusions: Multiple aggregometry ADP, ASPI, and TRAP tests seem to be able to detect primary hemostasis pathology (platelets aggregation and adhesion pathology) that is present during short-term perioperative ECMO support in lung transplantation procedures. Interestingly, RISTO tests seem to be more suitable How to cite this article:

show abstract

Multiple electrode aggregometry as a method for platelet function assessment according to the European guidelines

Cited by 8 publications

References 21 publications

Platelet Function in Trauma: Is Current Technology in Function Testing Missing the Mark in Injured Patients?

Platelet Function in Trauma: Is Current Technology in Function Testing Missing the Mark in Injured Patients?

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review

Extracorporeal membrane oxygenation seems to induce impairment of primary hemostasis pathology as measured by a Multiplate analyzer: An observational retrospective study

Contact Info

Product

Resources

About